Addition of the Oral NK 1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy

Purpose: This analysis evaluated whether the antiemetic efficacy of the NK 1 receptor antagonist aprepitant (EMEND ™ , Merck, Whitehouse Station, NJ) plus standard antiemetics could be sustained for up to six cycles of cisplatin-based chemotherapy. Patients and Methods: Patients receiving cisplatin...

Full description

Bibliographic Details

Published in:	Journal of clinical oncology Vol. 21; no. 22; pp. 4105 - 4111
Main Authors:	de Wit, R., Herrstedt, J., Rapoport, B., Carides, A.D., Carides, G., Elmer, M., Schmidt, C., Evans, J.K., Horgan, K.J.
Format:	Journal Article
Language:	English
Published:	15-11-2003
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!